Arbutus Biopharma Corporation ABUS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $169.7M+792% | -$3.76M+70.0% | -$7.74M+60.7% | $2.52M+113% | -$24.53M-37.2% | ||
| $11K-96.7% | $11K-96.7% | $11K-96.7% | $11K-96.9% | $330K-7.0% | ||
| $1.36M-61.9% | $1.26M-22.7% | $1.26M-41.5% | $864K-72.8% | $3.56M+77.0% | ||
| -$1.16M+5.5% | $0-100% | -$120K+24.5% | -$157K+57.8% | -$1.23M-438% | ||
| -$985K-122% | —— | —— | -$7.6M-366% | $4.55M+325% | ||
| $195K+147% | -$1.3M-12.6% | -$1.04M+12.2% | $1.05M+1,008% | -$413K-365% | ||
| -$105K-1.0% | -$177K-42.7% | -$155K+0.6% | -$121K-55.1% | -$104K-44.4% | ||
| $0+100% | —— | —— | -$9.62M-1,776% | -$812K-233% | ||
| $209K-30.1% | -$2.66M-241% | $268K-22.1% | $260K+23.2% | $299K+66.1% | ||
| $178.74M— | —— | —— | —— | $0— | ||
| -$8.11M+39.4% | -$4.68M+54.6% | -$5.82M+71.9% | -$15.75M-8.6% | -$13.39M+30.6% | ||
| $13.8M-60.2% | $25.55M-40.9% | $51.3M+27.2% | $28.5M-12.5% | $34.72M+36.7% | ||
| $16M-65.3% | $23.83M-58.0% | $41.28M+45.6% | $44.1M+4.0% | $46.07M+23.9% | ||
| $2.2M-80.6% | —— | —— | $15.61M+58.8% | $11.35M-3.0% | ||
| $11.53M+335% | $1.64M+15.3% | $794K-50.1% | $453K-77.5% | $2.65M+8.1% | ||
| $11.62M+317% | $1.64M+15.4% | $844K-52.5% | $453K-98.1% | $2.78M-88.6% | ||
| -$10K-350% | $1K+103% | —— | $21K+363% | $4K+131% | ||
| $5.7M+664% | -$4.4M-198% | -$15M— | $336K-98.3% | $746K-95.6% | ||
| $354K-50.7% | $422K-54.3% | $541K-45.0% | $668K-1.2% | $718K+29.8% | ||
| $209K-30.1% | -$2.66M-241% | $268K-22.1% | $260K+23.2% | $299K+66.1% | ||
| $178.74M— | —— | —— | —— | $0— | ||
| $0+100% | —— | —— | -$9.62M-1,776% | -$812K-233% | ||
| $195K+147% | -$1.3M-12.6% | -$1.04M+12.2% | $1.05M+1,008% | -$413K-365% | ||
| $17K-39.3% | $17K-41.4% | $23K-17.9% | $27K-20.6% | $28K-22.2% | ||
| $181K-59.6% | $259K-49.7% | $249K-56.5% | $526K-7.9% | $448K-24.5% | ||
| $0-100% | —— | —— | —— | $2.81M— | ||
| $16M-65.3% | $23.83M-58.0% | $41.28M+45.6% | $44.1M+4.0% | $46.07M+23.9% | ||
| $88K-32.8% | —— | $50K-73.0% | —— | $131K-37.9% | ||
| —— | -$4.68M+55.0% | -$5.82M+71.9% | -$15.75M-8.6% | -$13.39M+30.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
